ESTRO 2025 - Abstract Book

S1887

Clinical - Urology

ESTRO 2025

a PSA >100. In total, 42 patients (54 %) received a focal boost and 15 (19 %) were treated with a boost to positive lymph nodes. The 5-year bPFS was 76%, N0 patients had a bPFS of 82%. OS at five years was 95 %. The RTOG- scored ≥ 2 GU och GI toxicity is presented in Fig 1 and Fig 2.

Fig 1.

Fig 2.

Conclusion: Definitive radiotherapy comprising both intraprostatic boost and whole pelvic treatment, including boost to positive lymph nodes, is feasible with limited toxicity. However, this non-randomised study is hampered by its relatively small size, necessitating further studies.

Keywords: radiotherapy, prostate cancer, high-risk